secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001104659-24-023842
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics Q1 net loss $11.2M; NORSE EIGHT underway, SPA agreed, $172M financing
--------------------------------------------------------------------------------

- Net loss for Q1 FY2024 was $11.2M ($0.04/sh), compared to $18.7M ($0.08/sh) in prior year.
- Cash and equivalents at Dec 31, 2023: $10.4M; private placements for up to $172M (subject to shareholder approval).
- FDA SPA agreed on NORSE EIGHT protocol; first subject dosed Jan 2024. Success would satisfy second clinical trial requirement from CRL.
- BLA resubmission for ONS-5010 expected by end of CY2024; EU MAA decision targeted first half 2024.
- Company working to resolve CMC comments from CRL; expects resolution before NORSE EIGHT completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/0001104659-24-023842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924023842/tm246210d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-023842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer